All News

    FDA sBLA Submitted for Anktiva Plus BCG in Papillary Bladder Cancer

    April 16th 2025, 9:00pm

    Article

    A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

    TLX101 Demonstrated Efficacy in Recurrent High-Grade Glioma

    April 16th 2025, 7:00pm

    Article

    TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from the phase 2 IPAX-Linz study.

    15% of U.S. Cancer Patients Are Active Smokers at Time of Diagnosis

    April 16th 2025, 6:00pm

    Article

    The addition of smoking status to the National Cancer Database might inform more effective treatment for smokers with cancer.

    Sometimes, Distractions Help During Breast Cancer

    April 16th 2025, 5:00pm

    Article

    After a mammogram and breast cancer scare, a Broadway show provided a welcome distraction and joy, reminding me of life's beauty.

    Bria-IMT Combo Outperforms Other Metastatic Breast Cancer Treatments

    April 16th 2025, 4:00pm

    Article

    Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ metastatic breast cancer.

    Bexmarilimab Plus Vidaza Elicit Responses in Myelodysplastic Syndromes

    April 16th 2025, 3:05pm

    Article

    Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory higher-risk myelodysplastic syndrome.

    Understanding Esophageal Cancer: Early Signs, Risks and Key Insights

    April 16th 2025, 1:00pm

    Video

    Dr. Nataliya Uboha sat down to discuss the early warning signs of esophageal cancer, as well as important key takeaways for those with the disease.

    Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset

    April 15th 2025, 9:00pm

    Article

    Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.

    Subcutaneous Opdivo Similarly Effective, Safe as IV for Advanced ccRCC

    April 15th 2025, 7:00pm

    Article

    Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell carcinoma.

    Spring Looks Different This Year

    April 15th 2025, 5:00pm

    Article

    What is lovely never dies, but passes into other loveliness, Stardust or seafoam, flower or winged air. ― Thomas Bailey Aldrich